GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000193316 | Endometrium | EEC | negative regulation of protein phosphorylation | 59/2168 | 342/18723 | 1.11e-03 | 9.48e-03 | 59 |
GO:003298613 | Endometrium | EEC | protein-DNA complex disassembly | 8/2168 | 20/18723 | 1.11e-03 | 9.49e-03 | 8 |
GO:004232616 | Endometrium | EEC | negative regulation of phosphorylation | 65/2168 | 385/18723 | 1.13e-03 | 9.67e-03 | 65 |
GO:007177211 | Endometrium | EEC | response to BMP | 33/2168 | 165/18723 | 1.16e-03 | 9.90e-03 | 33 |
GO:007177311 | Endometrium | EEC | cellular response to BMP stimulus | 33/2168 | 165/18723 | 1.16e-03 | 9.90e-03 | 33 |
GO:000717313 | Endometrium | EEC | epidermal growth factor receptor signaling pathway | 24/2168 | 108/18723 | 1.18e-03 | 1.00e-02 | 24 |
GO:009008512 | Endometrium | EEC | regulation of protein deubiquitination | 6/2168 | 12/18723 | 1.19e-03 | 1.00e-02 | 6 |
GO:003202412 | Endometrium | EEC | positive regulation of insulin secretion | 19/2168 | 78/18723 | 1.19e-03 | 1.00e-02 | 19 |
GO:004315410 | Endometrium | EEC | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 19/2168 | 78/18723 | 1.19e-03 | 1.00e-02 | 19 |
GO:004329715 | Endometrium | EEC | apical junction assembly | 19/2168 | 78/18723 | 1.19e-03 | 1.00e-02 | 19 |
GO:006115713 | Endometrium | EEC | mRNA destabilization | 20/2168 | 84/18723 | 1.21e-03 | 1.02e-02 | 20 |
GO:009858611 | Endometrium | EEC | cellular response to virus | 20/2168 | 84/18723 | 1.21e-03 | 1.02e-02 | 20 |
GO:000182311 | Endometrium | EEC | mesonephros development | 22/2168 | 96/18723 | 1.22e-03 | 1.02e-02 | 22 |
GO:00030071 | Endometrium | EEC | heart morphogenesis | 45/2168 | 246/18723 | 1.24e-03 | 1.03e-02 | 45 |
GO:003166816 | Endometrium | EEC | cellular response to extracellular stimulus | 45/2168 | 246/18723 | 1.24e-03 | 1.03e-02 | 45 |
GO:007121613 | Endometrium | EEC | cellular response to biotic stimulus | 45/2168 | 246/18723 | 1.24e-03 | 1.03e-02 | 45 |
GO:003812713 | Endometrium | EEC | ERBB signaling pathway | 26/2168 | 121/18723 | 1.28e-03 | 1.06e-02 | 26 |
GO:003287813 | Endometrium | EEC | regulation of establishment or maintenance of cell polarity | 9/2168 | 25/18723 | 1.33e-03 | 1.10e-02 | 9 |
GO:006104114 | Endometrium | EEC | regulation of wound healing | 28/2168 | 134/18723 | 1.34e-03 | 1.10e-02 | 28 |
GO:00020901 | Endometrium | EEC | regulation of receptor internalization | 15/2168 | 56/18723 | 1.37e-03 | 1.13e-02 | 15 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AR | SNV | Missense_Mutation | | c.2595N>A | p.Asp865Glu | p.D865E | P10275 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
AR | SNV | Missense_Mutation | | c.1912N>A | p.Leu638Met | p.L638M | P10275 | protein_coding | tolerated(0.07) | benign(0.316) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
AR | SNV | Missense_Mutation | novel | c.1082N>A | p.Ser361Asn | p.S361N | P10275 | protein_coding | tolerated_low_confidence(0.27) | benign(0.015) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1681N>A | p.Leu561Met | p.L561M | P10275 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-BH-A18L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1703C>T | p.Ser568Phe | p.S568F | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
AR | SNV | Missense_Mutation | novel | c.2642N>A | p.Leu881Gln | p.L881Q | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-OL-A66K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | novel | c.585N>T | p.Gln195His | p.Q195H | P10275 | protein_coding | tolerated_low_confidence(0.13) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.2718N>T | p.Lys906Asn | p.K906N | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.967N>A | p.Glu323Lys | p.E323K | P10275 | protein_coding | tolerated_low_confidence(0.11) | benign(0.265) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
AR | SNV | Missense_Mutation | | c.2462G>T | p.Gly821Val | p.G821V | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | FLUOCINOLONE ACETONIDE | FLUOCINOLONE ACETONIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 4-CHLOROMERCURIBENZOIC ACID | 4-CHLOROMERCURIBENZOIC ACID | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | agonist | CHEMBL2107067 | TESTOSTERONE UNDECANOATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | DIDECYLDIMETHYLAMMONIUM CHLORIDE | DIDECYLDIMETHYLAMMONIUM CHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | QUININE SULFATE | QUININE SULFATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | NILUTAMIDE | NILUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | RALOXIFENE HYDROCHLORIDE | RALOXIFENE HYDROCHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | ARN-509 | APALUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | CRUFOMATE | CRUFOMATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 2-AMINOFLURENE | CHEMBL84472 | |